Issue 38, 2024

Compelling DNA intercalation through ‘anion–anion’ anti-coulombic interactions: boron cluster self-vehicles as promising anticancer agents

Abstract

Anticancer drugs inhibit DNA replication by intercalating between DNA base pairs, forming covalent bonds with nucleotide bases, or binding to the DNA groove. To develop safer drugs, novel molecular structures with alternative binding mechanisms are essential. Stable boron hydrides offer a promising alternative for cancer therapy, opening up additional options like boron neutron capture therapy based on 10B and thermal neutron beams or proton boron fusion therapy using 11B and proton beams. These therapies are more efficient when the boron compound is ideally located inside cancer cells, particularly in the nucleus. Current cancer treatments often utilize small, polycyclic, aromatic, planar molecules that intercalate between ds-DNA base pairs, requiring only a spacing of approximately 0.34 nm. In this paper, we demonstrate another type of intercalation. Notably, [3,3′-Fe(1,2-C2B9H11)2], ([o-FESAN]), a compact 3D molecule measuring 1.1 nm × 0.6 nm, can as well intercalate by strong non-bonding interactions preferentially with guanine. Unlike known intercalators, which are positive or neutral, [o-FESAN] is a negative species and when an [o-FESAN] molecule approaches the negatively charged DNA phosphate chain an anion–anion interaction consistently anti-electrostatic via Ccluster–H⋯O–P bonds occurs. Then, when more molecules approach, an elongated outstandingly self-assembled structure of [o-FESAN]–[o-FESAN] forms moving anions towards the interthread region to interact with base pairs and form aggregates of four [o-FESAN] anions per base pair. These aggregates, in this environment, are generated by Ccluster–H⋯O–C, N–H⋯H–B and Ccluster–H⋯H–B interactions. The ferrabis(dicarbollide) boron-rich small molecules not only effectively penetrate the nucleus but also intercalate with ds-DNA, making them promising for cancer treatment. This amphiphilic anionic molecule, used as a carrier-free drug, can enhance radiotherapy in a multimodal perspective, providing healthcare professionals with improved tools for cancer treatment. This work demonstrates these findings with a plethora of techniques.

Graphical abstract: Compelling DNA intercalation through ‘anion–anion’ anti-coulombic interactions: boron cluster self-vehicles as promising anticancer agents

Supplementary files

Article information

Article type
Paper
Submitted
31 May 2024
Accepted
02 Aug 2024
First published
07 Aug 2024
This article is Open Access
Creative Commons BY-NC license

J. Mater. Chem. B, 2024,12, 9550-9565

Compelling DNA intercalation through ‘anion–anion’ anti-coulombic interactions: boron cluster self-vehicles as promising anticancer agents

L. Gutiérrez-Gálvez, T. García-Mendiola, E. Lorenzo, M. Nuez-Martinez, C. Ocal, S. Yan, F. Teixidor, T. Pinheiro, F. Marques and C. Viñas, J. Mater. Chem. B, 2024, 12, 9550 DOI: 10.1039/D4TB01177E

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements